Repositioning Candidate Details
| Candidate ID: | R1405 |
| Source ID: | DB11781 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Tosedostat |
| Synonyms: | Tosedostat |
| Molecular Formula: | C21H30N2O6 |
| SMILES: | CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Tosedostat has been used in trials studying the treatment and supportive care of AML, Leukemia, Pancreas Cancer, Multiple Myeloma, and Pancreatic Cancer, among others. Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel. It entered the clinical trial in patients with haematological malignancies. |
| CAS Number: | 238750-77-1 |
| Molecular Weight: | 406.479 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | Tosedostat has pleiotropic effects against a range of human tumor cell lines originating from diverse tumor types in vitro and in vivo. |
| DrugBank MoA: | Tosedostat is anti-proliferative agent which induces apoptosis in leukemic cell lines in vitro. The mechanism underlying these anti-cancer actions is unclear, particularly since normal cells are much less sensitive to the agents than transformed cells. It exerts potent anti-proliferative, pro-apoptotic and anti-angiogenic effects in vitro and shows selectivity for transformed over non-transformed cells. It inhibits a number of M1 aminopeptidase enzyme family members in vitro (eg puromycin-sensitive aminopeptidase (PSA), leukotriene A4 hydrolase (LTA4H)). |
| Targets: | Puromycin-sensitive aminopeptidase; Leukotriene A-4 hydrolase |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|